This review concluded that subcutaneous interferon-beta-1a (Rebif) or subcutaneous interferon-beta-1b (Betaferon) worked better than intramuscular interferon-beta-1a (Avonex), whilst Betaferon was even better than Rebif in management of relapsing-remitting multiple sclerosis, although the results were not statistically significant. These conclusions should be interpreted with caution, given the limitations of the included studies.
Searching
The following databases were searched for English language studies from 1966 to July 2009: PubMed, Scopus, Web of Science and Cochrane Central Register of Controlled Trials. Search terms were reported. The reference lists from retrieved publications were also screened. Conference proceedings were also considered for inclusion (details not reported).
Study selection
Controlled studies that compared three different formulations of interferon-beta, including intramuscular interferonbeta-1a (Avonex), subcutaneous interferon-beta-1a (Rebif) and subcutaneous interferon-beta-1b (Betaseron or Betaferon), in patients with multiple sclerosis were eligible for inclusion. Studies that compared any formulations of interferon-beta with only placebo were excluded.
The eligible outcomes were mean change in Expanded Disability Status Scale and number of patients with at least one relapse.
For included studies that compared Avonex with Rebif, the dosage regimen of Avonex was 30μg per week and the dosage regimen of Rebif ranged from 22 to 44μm three times per week. For included studies that compared Avonex with subcutaneous Betaseron, the dosage regimen of Avonex was 6MIU per week and the dosage regimen of Betaseron was 8MIU on alternate days. For included studies that compared Rebif and Betaseron, the dosage regimen of Rebif ranged from 22 to 44μg once to three times per week and the dosage regimen of Betaseron was 250μg on alternate days. The duration of treatment in included studies ranged from 48 weeks to two years. All the included patients had relapsing-remitting multiple sclerosis. The patients' mean age in included studies ranged from 28 to 38 years; most included patients were females. The included studies were published from 2001 to 2007.
Three reviewers independently assessed studies for inclusion, with any disagreement resolved by consensus.
Assessment of study quality
The quality of studies was assessed using the Jadad scale, a 5-point scale evaluating randomisation, blinding and withdrawals. Studies scoring at least 5 were classified as high quality.
The authors did not report how many reviewers performed the validity assessment.
Data extraction
For dichotomous outcomes, event rates were extracted to enable the calculation of relative risks (RRs) with 95% confidence interval (CIs). For continuous outcomes, means and standard deviations were extracted to enable the calculation of mean differences (MDs) and 95% confidence intervals.
Three reviewers independently performed the data extraction, with any disagreement resolved by consensus.
Methods of synthesis
The included studies were combined in meta-analyses. The pooled relative risks and 95% confidence intervals were calculated using the DerSimonian-Laird random-effects model. The authors reported that there were insufficient data to pool mean change in Expanded Disability Status Scale. Statistical heterogeneity was assessed using the Cochran Q test. The heterogeneity of effect estimates was explored using the L'Abbe plot. Publication bias was assessed using a funnel plot and Kendall's test.
Results of the review
Six studies (four clinical controlled trials and two observational cohort studies) were included in the review (n=5,266 patients). The quality score of trials ranged from 0 to 4 points. Only one trial was classified as high quality.
There was a marginally significant reduction in the rate of patients with at least one relapse for subcutaneous interferonbeta-1a (Rebif) compared with subcutaneous interferon-beta-1b (Betaferon) (RR 0.90, 95% CI 0.82 to 1.00; three studies). No significant heterogeneity was observed in this outcome (p=0.32).
No significant differences in the rate of patients with at least one relapse were observed for intramuscular interferonbeta-1a (Avonex) compared with subcutaneous Rebif (RR 0.85, 95% CI 0.57 to 1.25; three studies; p<0.0001) and for Avonex compared with Betaferon (RR 0.91, 95% CI 0.75 to 1.10; four studies; p=0.03). Significant heterogeneity was observed for both outcomes.
There was some evidence of publication bias among studies that compared Avonex with Betaferon. It was not possible to assess publication bias for the remaining comparisons.
